GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » Accounts Receivable

Organogenesis Holdings (Organogenesis Holdings) Accounts Receivable : $96.1 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Organogenesis Holdings's accounts receivables for the quarter that ended in Mar. 2024 was $96.1 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Organogenesis Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 79.78.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Organogenesis Holdings's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.04.


Organogenesis Holdings Accounts Receivable Historical Data

The historical data trend for Organogenesis Holdings's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings Accounts Receivable Chart

Organogenesis Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only 39.36 56.80 82.46 89.45 82.00

Organogenesis Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.02 93.62 89.28 82.00 96.15

Organogenesis Holdings Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Organogenesis Holdings Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Organogenesis Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=96.148/109.976*91
=79.78

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Organogenesis Holdings's accounts receivable are only considered to be worth 75% of book value:

Organogenesis Holdings's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(88.626+0.75 * 96.148+0.5 * 27.694-180.451
-0-0)/132.539
=-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Organogenesis Holdings Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Organogenesis Holdings (Organogenesis Holdings) Business Description

Traded in Other Exchanges
Address
85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Executives
Albert Erani 10 percent owner 150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz 10 percent owner
Arthur S Leibowitz director 139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Michael Joseph Driscoll director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney director, officer: President and CEO C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gilberto Quintero director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin director 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo officer: VP Health Policy & Contracting C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin director 7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu director C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf director, 10 percent owner
Alan A. Ades director, 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021

Organogenesis Holdings (Organogenesis Holdings) Headlines

From GuruFocus